Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 43Carcinoma, Hepatocellular 19Rectal Neoplasms 10Colonic Neoplasms 10Neoplasm Metastasis 9Gastrointestinal Stromal Tumors 8Sarcoma 5Ovarian Neoplasms 5Cholangiocarcinoma 5Melanoma 4Pancreatic Neoplasms 3Osteosarcoma 3Liver Neoplasms 3Glioblastoma 3Stomach Neoplasms 2Neoplasms 2Lung Neoplasms 2Gallbladder Neoplasms 2Fatigue 2Esophageal Neoplasms 2Colorectal Cancer Metastatic 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Adenocarcinoma 2Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1Thyroid Neoplasms 1Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1

Interventions

pembrolizumab 3apatinib 3Magnetic Resonance Spectroscopy 3lenvatinib 2Specimen Handling 2Nivolumab 2Imatinib Mesylate 2Epirubicin 2Cisplatin 2Carboplatin 2Axitinib 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2regorafenib 1gallium 68 PSMA-11 1enfortumab vedotin 1cabozantinib 1avelumab 1anlotinib 1amivantamab 1Tretinoin 1Sunitinib 1Radiation 1Pemetrexed 1Nelfinavir 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Lutetium-177 1Lutetium 1Ipilimumab 1Glutamate Carboxypeptidase II 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Adenoid Cystic × regorafenib × Clear all
NCT02098538 2025-09-10

Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
38 enrolled 10 charts

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡